GLP-1 Drug Effectiveness Reduced by Genetic Variants
Key Points Summary Genetic variants in the PAM enzyme may reduce response to GLP-1 receptor agonists Around 10% of individuals
Read MoreKey Points Summary Genetic variants in the PAM enzyme may reduce response to GLP-1 receptor agonists Around 10% of individuals
Read MoreResearchers examined clinical data on the benefits of glucagon-like peptide-1 (GLP-1) medications beyond glycemic and weight control in a recent
Read MoreA group of researchers used a propensity-score matched cohort to assess the 12-month neurological and psychiatric outcomes of semaglutide use
Read MoreAccording to recent studies, people with diabetes may benefit further from the combination use of glucagon-like peptide-1 receptor agonists (GLP1-RAs)
Read MoreResearchers examined whether metformin medication is connected with a lower incidence of all-cause dementia in patients with type 2 diabetes
Read MoreFor two years, thousands of scientists and doctors around the world have been working to understand how COVID-19 develops and
Read MoreScientists at Nanyang Technological University, Singapore’s (NTU Singapore) Lee Kong Chian School of Medicine (LKCMedicine) have mapped a novel cellular
Read MorePeople who have difficulty getting to sleep or staying asleep had higher blood sugar levels than people who rarely had
Read MoreHigh blood glucose is responsible for several complications in type 1 and type 2 diabetes. Researchers at Karolinska Institutet in
Read MoreHaving COVID-19 appears to raise a person’s risk of developing diabetes within the next year by about 40%, according to
Read More